Good news: the Wegovy pen is covered by more plans than ever. See if yours qualifies
Medicare GLP‑1 Bridge · Part D insurance · $39/moCheck my coverage
FDA approvedFSA & HSA eligibleCovered by many plans
Get started on Wegovy pen, if prescribed
Wegovy pen
with semaglutide · through insurance
The FDA-approved weekly GLP-1 pen, prescribed by a clinician who understands what you have been through. We check your insurance first, so you know what is covered before you pay.
- An FDA-approved GLP-1 injection for chronic weight management
- Clinically shown to help people lose about 15% of their body weight in studies*
- We verify your benefits and handle prior authorization for you
- A clinician who stays with you the whole way
Wegovy is a once-weekly GLP-1 injection containing semaglutide, FDA-approved for chronic weight management.
What’s similar
- A once-weekly injection you take at home
- Started low and increased gradually by your clinician
- Prescription only, with ongoing clinical follow-up
What’s different
- Semaglutide works on one gut hormone, GLP-1
- In the head-to-head SURMOUNT-5 study, tirzepatide showed greater average loss, but both are effective, FDA-approved options
- Covered by many commercial and Medicare plans — we check your benefits first
- Your medication is billed through your insurance, separately from the Body Good program
Your $95 insurance processing fee is charged once, today; your $75/mo program then starts one month later — the medication is billed through your insurance. With coverage, your Wegovy pen can cost as little as $25/month through the manufacturer savings offer, if you are eligible.
- Insurance processing fee — $95 (charged once, today — the only charge today)
- Monthly program — $75/mo (starts one month after enrollment)
- Quarterly program — $195 ($65/mo · save $120/yr · starts 3 months after enrollment)
Prescription only. Your clinician determines the medicine and the dose after reviewing your health history — you state a preference, and the clinician may prescribe something different, or nothing at all.
Safety info: GLP-1 medicines carry a Boxed Warning for the risk of thyroid C-cell tumors and are contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. This page is not medical advice. See more serious warnings & safety info
Physician-led telehealthLegitScript-certifiedCoverage-first — we chase your insuranceFirst into Medicare
Real science, real results
15%
average body weight lost*
In the 68-week STEP 1 study, adults on Wegovy (semaglutide 2.4 mg) lost about 14.9% of their body weight on average — roughly 35 lbs for many — alongside a reduced-calorie plan and more activity.*
Your Wegovy estimate
232lbs
Potential weight lost over the study period*
35lbs
*Illustrative estimate based on average results in clinical studies of semaglutide 2.4 mg (STEP 1). Individual results vary. Not a guarantee of results or medical advice. A trial average — not a prediction of your result.
Semaglutide vs. tirzepatide
How the two medicines compare, head to head
In SURMOUNT-5, the first study to compare the two medicines directly, adults on tirzepatide lost more weight on average than those on semaglutide over 72 weeks.
TirzepatideZepbound / Mounjaro
−20.2%
SemaglutideWegovy / Ozempic
−13.7%
SURMOUNT-5: a 72-week randomized study comparing maximum-tolerated tirzepatide (10/15 mg) with maximum-tolerated semaglutide (1.7/2.4 mg). Mean weight change was −20.2% with tirzepatide vs −13.7% with semaglutide. Both are effective, FDA-approved options; the right one for you is a clinical decision. Individual results vary.
Meet
Wegovy pen
Why women choose it
GLP-1 power in a pen
FDA approved
FDA approved for chronic weight management. No gray-area guesswork.
Proven results
Clinically shown to help people lose about 15% of their body weight in studies.*
Covered by many plans
We check your commercial or Medicare benefits first, so you know your cost before you commit.
−14.9% average
semaglutide 2.4 mg weekly, 68 weeks (STEP-1) — a trial average, not a prediction of your result
How your clinician chooses a medicine
Is using medication to lose weight cheating?
Injection, pill, or pen?
100% online. Zero waiting rooms.
Getting started is simple
From the first visit to insurance support, we help you get — and stay — on track.
Start in 3 simple steps
No surprises, ever
Insurance pricing
One clear path: we use your insurance first, and you always see the price before you decide anything.
Best value with commercial insurance
With coverage, your Wegovy pen can cost as little as $25 / month through the manufacturer savings offer, if you are eligible.
Insurance concierge
One-time insurance processing fee
$95
charged once, today — the only charge today
Choose your starting dose
You select your starting dose upfront; your clinician confirms it and your titration. Your $95 insurance processing fee is charged once, today; your $75/mo program then starts one month later — the medication is billed through your insurance.
Your $95 insurance processing fee includes
- Benefit verification and processing
- A clinician consultation
- Prior authorization handling
- Your prescription, if you are approved
- Pharmacy coordination
Choose your ongoing plan
Selected: Monthly — $75 /mo · starts one month after enrollment, then every month
Your ongoing plan includes
- Dose adjustments
- Refill processing
- Unlimited support
- Continued insurance concierge if needed
Check my coverage
Medication cost depends on your plan and dose. Savings-offer eligibility applies (commercial insurance only; not valid with government insurance such as Medicare or Medicaid).
Want to skip the insurance process?
Buy brand-name the Wegovy pen self-pay — no prior authorization, transparent pricing, ships fast.
Prefer we handle the whole insurance process?
Our GLP-1 Coverage Concierge does the eligibility check, prior authorization, appeals, and refills for you — start to finish.
Women on the Wegovy pen
95% feel genuinely supported
“My insurance covered it, and I finally stopped fighting food all day.”
“Once a week, no fuss. They checked my coverage in a minute. No lectures.”
“I got my energy back, and my clinician actually listens. That is new for me.”
“Body Good handled everything for me. Painless, and the results speak for themselves.”
Paid testimonials. Results have not been independently verified. Individual results will vary.
What’s included in the Body Good membership?
- Benefit verification and processing
- A clinician consultation and prescription review
- Prior authorization, filed and handled by us
- Pharmacy coordination and refill processing
- Dose adjustments as you go
- Unlimited support from your care team
Explore your GLP‑1 options
- A full range of GLP-1 options, branded and personalized
- Insurance pursued first, or transparent self-pay pricing
- Prepay plans unlock our lowest monthly price
Physician-led care, customized to your goals.
Dr. Linda Moleon — founder, Obesity Medicine Specialist. The same clinicians build your plan, file your prior authorization, and follow you refill after refill, in English and Spanish.
Meet the care team
Wegovy pen, answered
Wegovy is a once-weekly GLP-1 injection containing semaglutide, FDA-approved for chronic weight management.
Wegovy (semaglutide) works on one gut hormone, GLP-1. Zepbound (tirzepatide) works on two. In the head-to-head SURMOUNT-5 study, tirzepatide showed greater average loss, but both are effective, FDA-approved options.
Many commercial and Medicare plans cover Wegovy. Our free 60-second coverage check confirms your benefits before you pay anything.
You can skip insurance and buy the Wegovy pen self-pay. See self-pay pricing.
Most common are nausea, diarrhea, and constipation, which often ease over time. Wegovy carries a Boxed Warning about thyroid C-cell tumors. See full safety information below.
See if the Wegovy pen is covered for you
Start with a free insurance check. Real care is a few minutes away.
Check my coverageImportant safety information
What you should know before taking Wegovy pen.
Boxed Warning: Risk of thyroid C-cell tumors. In rodents, semaglutide caused thyroid C-cell tumors. It is not known whether it causes these tumors, including medullary thyroid carcinoma (MTC), in people. Do not use if you or any family member have ever had MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or if you are allergic to semaglutide.
Wegovy (semaglutide) is a prescription medicine used with a reduced-calorie meal plan and increased physical activity for chronic weight management in certain adults. It may cause serious side effects, including inflammation of the pancreas (pancreatitis), gallbladder problems, low blood sugar, kidney problems, and serious allergic reactions. The most common side effects are gastrointestinal — nausea, diarrhea, vomiting, and constipation. Tell your clinician about all your medical conditions and medications.
This page is for informational purposes and is not medical advice. Talk to a licensed clinician about whether this treatment is right for you. For full prescribing information and the Medication Guide, see the manufacturer's official materials.